Skip to main content

REVIEW article

Front. Pharmacol.
Sec. Ethnopharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1443667
This article is part of the Research Topic Reviews in Ethnopharmacology: 2023 View all 24 articles

A review of Phyllanthus urinaria L. in the treatment of Liver disease: Viral Hepatitis, Liver Fibrosis/Cirrhosis and Hepatocellular Carcinoma

Provisionally accepted
Xie-an Yu Xie-an Yu *Linhua Liu Linhua Liu Bing Wang Bing Wang Yibo Ma Yibo Ma Kunhui Sun Kunhui Sun Ping Wang Ping Wang Meifang Li Meifang Li Junlin Dong Junlin Dong Meirong Qin Meirong Qin Mingshun Li Mingshun Li Chunshan Wei Chunshan Wei Ying Tan Ying Tan Jinsong He Jinsong He Keying Guo Keying Guo
  • Shenzhen Institute For Drug Control, Shenzhen, China

The final, formatted version of the article will be published soon.

    Due to the pathological production of liver disease in utility particularly complexity, the morbidity and mortality of liver disease including viral hepatitis, liver fibrosis/cirrhosis and hepatocellular carcinoma (HCC) are rapidly increasing worldwide. Considering its insidious onset, rapid progression and drug resistance, finding an effective therapy is particularly worthwhile. Phyllanthus urinaria L. (P. urinaria), an ethnic medicine, can be applied at the stages of viral hepatitis, liver fibrosis/cirrhosis and HCC, which demonstrates great potential in the treatment of liver disease. Currently, there are numerous reports on the application of P. urinaria in treating liver diseases, but a detailed analysis of its metabolites and a complete summary of its pharmacological mechanism are still scarce. In this review, the phytochemical metabolites and ethnopharmacological applications of P. urinaria are summarized. Briefly, P. urinaria mainly contains flavonoids, lignans, tannins, phenolic acids, terpenoids and other metabolites. The mechanisms of P. urinaria are mainly reflected in reducing surface antigen secretion and interfering with DNA polymerase synthesis for anti-viral hepatitis activity, reducing hepatic stellate cells activity, inflammation and oxidative stress for anti-liver fibrosis/cirrhosis activity, as well as preventing tumor proliferation, invasion and angiogenesis for anti-HCC activity via relevant signaling pathways. Accordingly, this review provides insights into the future application of natural products in the trilogy of liver diseases and will provide a scientific basis for further research and rational utilization of P. urinaria.

    Keywords: Phyllanthus urinaria L., Liver disease, Viral Hepatitis, Liver Fibrosis/Cirrhosis, Hepatocellular Carcinoma Abbreviations: HCC, Hepatocellular Carcinoma, P. urinaria, Phyllanthus urinaria L., HSCs, hepatic stellate cells, HBV, hepatitis B virus, HCV, hepatitis C virus, NAFLD, nonalcoholic fatty liver disease, HBX, hepatitis B virus X protein, EBV, Epstein-Barr virus

    Received: 04 Jun 2024; Accepted: 23 Jul 2024.

    Copyright: © 2024 Yu, Liu, Wang, Ma, Sun, Wang, Li, Dong, Qin, Li, Wei, Tan, He and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Xie-an Yu, Shenzhen Institute For Drug Control, Shenzhen, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.